931TiPPRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. (23rd October 2018) - Collinson, F; Brown, S; Buckley, H; Ainsworth, G; Howard, H; Poad, H; Carr, G; Banks, R E; Brown, J; Velikova, G; Larkin, J; Nathan, P; et al.